Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reyataz-based substitution in management of HIV-associated lipodystrophy
2004-002740-10Phase 4Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of atazanavir in human immunodeficiency virus infection (HIV) and lipodystrophy (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Change in trunk-to-limb fat ratio at week 48 (DEXA). Started Apr 2005; status: completed.
02
Drugs
atazanavir
03
Conditions
human immunodeficiency virus infection (HIV)lipodystrophy
Beyond the preview
Go deeper on 2004-002740-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002740-10.